Vancomycin hydrochloride (manufactured in Budapest, Hungary)

Vancomycin hydrochloride (manufactured in Budapest, Hungary)
Product Description

Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, enterococci, (e.g. Enterococcus faecalis), Streptococcus bovis and viridans group streptococci.

Indication: Used in the treatment of severe systemic methicillin resistant (MRSA) and sensitive strains where other antibiotics cannot be used due to intolerance or drug resistance. May be administered orally for treating antibiotic-associated pseudomembranous colitis produced by Clostridium difficile and for staphylococcal enterocolitis.

Application: Administered systemically as intravenous infusions and as capsules for oral administration. IV form can also be used orally for the treatment of Clostridium difficile infections.

Shelf-life: 2 years (according to Ph. Eur.); 3 years (according to USP)

Storage conditions: Below 8°C (46°F)

For further information contact us at [email protected]

or access our product sheet online https://www.xellia.com/products/Vancomycin%20Hydrochloride%20-%20Budapest/

Read more Show less

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer
View company profile
Categories
more categories Show less

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer
View company profile

More Products from Xellia Pharmaceuticals ApS (21)

  • Colistimethate sodium (CMS)

    Product Colistimethate sodium (CMS)

    Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

    I...
  • Daptomycin

    Product Daptomycin

    Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol...
  • Gramicidin

    Product Gramicidin

    Gramicidin is a mixture of linear polypeptides active against a variety of Gram-positive bacteria.

    Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria, such...
  • Polymyxin B sulfate

    Product Polymyxin B sulfate

    Polymyxin B sulfate is a mixture of sulfates of polypeptide antibiotics active against Pseudomonas aeruginosa and other Gram-negative bacteria.

    Indication: Used in the treatment of acute urinary, meningeal or blood stream infections due to Pseudomonas aeruginosa and other ...
  • Tobramycin sulfate

    Product Tobramycin sulfate

    Tobramycin sulfate is the sulfate salt of tobramycin, an aminoglycoside antibiotic active against Gram-negative bacteria including most Enterobacteriaceae, Pseudomonas aeruginosa and a few Gram-positive bacteria such as Staphylococcus aureus.

    Indication: Use...
  • Tyrothricin

    Product Tyrothricin

    Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.

    ...
  • Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)

    Product Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...
  • Vancomycin hydrochloride (manufactured in Taizhou, China)

    Product Vancomycin hydrochloride (manufactured in Taizhou, China)

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...
  • Bacitracin vials

    Product Bacitracin vials

    Bacitracin is comprised of a polypeptide complex and bacitracin A is the major component in this complex active against a variety of Gram-positive bacteria and a few Gram-negative bacteria, however only staphylococcal infections qualify for the systemic therapy.

    Indi...
  • Colistimethate sodium lyophilized vials

    Product Colistimethate sodium lyophilized vials

    Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.

    Indication:&nbs...
  • Daptomycin RT

    Product Daptomycin RT

    Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
    Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus&nbs...
  • Daptomycin vials

    Product Daptomycin vials

    Daptomycin is a lipopeptide antibacterial agent active against Gram-positive bacteria.

    Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of Gram-positive bacteria such as Staphylococcus au...
show all 21 other products

Xellia Pharmaceuticals ApS resources (2)

  • Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

    News Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

    Copenhagen, Denmark, 2 October 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer. With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies.
    3 Oct 2023
  • Xellia Corporate Introduction

    Technical Data Xellia Corporate Introduction

    Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.